Atracurium Besylate
FDA-approved product (injectable, injection), marketed as Atracurium Besylate, Atracurium Besylate Preservative Free, Tracrium and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neuromuscular Blockade
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other quaternary ammonium compounds
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Atracurium Besylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Evaluating the Influence of the Strategy Intraoperative Anesthetic (Desflurane Versus Propofol) on Cognitive and Psychomotor Functions in Output Post Interventional Room Monitoring - COGNIDES
NCT02036736 · start 2013-04
Registered record
- Registry ID
- NCT02036736
- Conditions
- Orthopedic Surgery; Total Hip Prosthesis; Total Knee Replacement
- Interventions
- Intraoperative anesthetic strategy by Propofol; Intraoperative anesthetic strategy by Desflurane
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-04
- Completion
- 2014-12
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOrthopedic Surgery; Total Hip Prosthesis; Total Knee ReplacementInterventionIntraoperative anesthetic strategy by Propofol; Intraoperative anesthetic strategy by DesfluranePhasePhase 2Registry statusCompletedSugammadex: Effect on the Awareness Monitoring and Hemodynamics
NCT01301261 · start 2010-12
Registered record
- Registry ID
- NCT01301261
- Conditions
- Surgical Procedure, Unspecified
- Interventions
- sugammadex; Sugammadex 4 mg/kg; Sugammadex 16mg/kg
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2010-12
- Completion
- Not recorded
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSurgical Procedure, UnspecifiedInterventionsugammadex; Sugammadex 4 mg/kg; Sugammadex 16mg/kgPhaseNot applicableRegistry statusUnknownEffect of Acute Arterial Hypertension on Morphine's Requirements and Postsurgical Pain.
NCT01897155 · start 2010-01
Registered record
- Registry ID
- NCT01897155
- Conditions
- Hypertensive Disease; Pain, Postoperative
- Interventions
- SBP 20-30% over baseline; SBP 20-30% under baseline
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-01
- Completion
- 2012-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensive Disease; Pain, PostoperativeInterventionSBP 20-30% over baseline; SBP 20-30% under baselinePhasePhase 4Registry statusCompletedEffect of Epidural Anesthesia and Analgesia on Patients' Outcomes After Liver Resection
NCT01617811 · start 2007-08
Registered record
- Registry ID
- NCT01617811
- Conditions
- Hepatectomy
- Interventions
- epidural anesthesia and analgesia
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-08
- Completion
- 2008-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatectomyInterventionepidural anesthesia and analgesiaPhaseNot applicableRegistry statusCompletedEffect of Nitrous Oxide on Cisatracurium Infusion Demands
NCT01152905 · start 2007-04
Registered record
- Registry ID
- NCT01152905
- Conditions
- Neuromuscular Blocking Agents
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2008-07
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeuromuscular Blocking AgentsInterventionNot recordedPhaseNot recordedRegistry statusCompleted